CLRB (Cellectar Biosciences) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLRB Cellectar Biosciences Inc CLRB
19 GF Score
Price $2.63
! 1 Warning Sign
View Full Analysis

What is Cellectar Biosciences Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

CLRB
19GF Score
Cellectar Biosciences Inc CLRB
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cellectar Biosciences Business Description

Address 100 Campus Drive, Florham Park, NJ, USA, 07932
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
19GF Score

Get the complete analysis for CLRB

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.63
Price